Alvotech (ALVO) Non Operating Interest Expenses (2021 - 2026)
Alvotech's (ALVO) quarterly Non Operating Interest Expenses came in at -$41.0 million in Q2 2026, down 11.93% on a YoY basis from -$46.6 million in Q2 2025, and down 0.53% quarter-over-quarter from -$40.8 million in Q1 2026.
Analysis
Alvotech (ALVO) Non Operating Interest Expenses (2021 - 2026) Analysis & Trends
Alvotech (ALVO) has reported Non Operating Interest Expenses for 6 consecutive years, with -$41.0 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Non Operating Interest Expenses fell 11.93% year-over-year to -$41.0 million; the trailing twelve-month figure through Jun 2026 stood at -$319.5 million (up 4.8% YoY), and the FY2025 full-year result was -$149.2 million, up 50.79% from the prior year.
- Non Operating Interest Expenses eased to -$41.0 million in Q2 2026 per ALVO's latest filing, from -$40.8 million in the prior quarter.
- Across five years, Non Operating Interest Expenses topped out at $240.8 million in Q2 2022 and bottomed at -$303.2 million in Q4 2024.
- Historically, Non Operating Interest Expenses has averaged -$87.6 million across 5 years, with a median of -$68.2 million in 2023.
- The widest YoY moves for Non Operating Interest Expenses: up 80.69% in 2025, down 516.53% in 2025.
- Over 5 years, Non Operating Interest Expenses stood at -$188.4 million in 2022, then slumped by 41.79% to -$267.2 million in 2023, then declined by 13.48% to -$303.2 million in 2024, then surged by 76.19% to -$72.2 million in 2025, then jumped by 43.17% to -$41.0 million in 2026.
- According to Business Quant data, Non Operating Interest Expenses over the past three periods registered -$41.0 million, -$40.8 million, and -$72.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.34 Bn | 38.68 Bn | 2.15 Bn | - |
| 2 | Viatris | 19.39 Bn | 18.50 Bn | 1.46 Bn | 120.70 Mn |
| 3 | Dr Reddys Laboratories | 9.99 Bn | 9.85 Bn | 396.53 Mn | -13.26 Mn |
| 4 | Amneal Pharmaceuticals | 5.57 Bn | 5.53 Bn | 334.51 Mn | - |
| 5 | Bausch Health Companies | 2.45 Bn | 1.58 Bn | 2.10 Bn | 396.00 Mn |
| 6 | Ani Pharmaceuticals | 1.70 Bn | 1.34 Bn | 165.89 Mn | - |
| 7 | Alvotech | 1.66 Bn | 1.52 Bn | 2.56 Mn | -41.02 Mn |
| 8 | Amphastar Pharmaceuticals | 985.90 Mn | 695.77 Mn | 93.47 Mn | 6.66 Mn |
| 9 | Fennec Pharmaceuticals | 434.07 Mn | 392.82 Mn | 17.15 Mn | 3,000.00 |
| 10 | NutriBand | 72.57 Mn | 69.15 Mn | 181,874.00 | 4,874.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -41.02 Mn |
| Mar 31, 2026 | -40.81 Mn |
| Dec 31, 2025 | -72.19 Mn |
| Sep 30, 2025 | -165.49 Mn |
| Jun 30, 2025 | -36.65 Mn |
| Mar 31, 2025 | -35.54 Mn |
| Dec 31, 2024 | -303.17 Mn |
| Sep 30, 2024 | 39.73 Mn |
| Jun 30, 2024 | -93.35 Mn |
| Mar 31, 2024 | -184.06 Mn |
| Dec 31, 2023 | -267.16 Mn |
| Aug 31, 2023 | -64.30 Mn |
| Jun 30, 2023 | 143.30 Mn |
| Mar 20, 2023 | -267.16 Mn |
| Dec 31, 2022 | -188.42 Mn |
| Aug 31, 2022 | -52.41 Mn |
| Jun 30, 2022 | 240.83 Mn |
| Mar 20, 2022 | -188.42 Mn |
| Dec 31, 2021 | -117.36 Mn |
| Sep 30, 2021 | -33.78 Mn |